Anti-B7-H4 antibodies and immunoconjugates

Inventors: Steven R. Leong (Berkeley, CA); Andrew Polson (San Francisco, CA); Paul Polakis (Mill Valley, CA); Yan Wu (Foster City, CA); Wei-Ching Liang (Foster City, CA); Ron Firestein (Burlingame, CA)

Assignee: Genentech, Inc.

C07K16/2827 A61K31/404 A61K31/5517 A61K31/706 A61K38/05 A61K47/6803 A61K47/6809 A61K47/6855 A61K47/6869 C07K16/3015 C07K16/3069 G01N33/57492 C07K2317/24 C07K2317/31 C07K2317/33 C07K2317/565 C07K2317/567 C07K2317/73 C07K2317/77 C07K2317/92

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 10,059,768
App. No.: 14/851,003
Granted: Aug 28, 2018
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The invention provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same.

Claims (33)

1. A bi-epitopic antibody comprising a first half antibody and a second half antibody, wherein the first half antibody comprises a first VH/VL unit that binds a first epitope of B7-H4, and wherein the second half antibody comprises a second VH/VL unit that binds a second epitope of B7-H4, wherein the first half antibody binds an epitope within all or a portion of the B7-H4 Ig-V containing domain and the second half antibody binds an epitope within all or a portion of the B7-H4 Ig-V and Ig-C containing domains; or wherein the first half antibody binds an epitope within all or a portion of the B7-H4 Ig-V and Ig-C containing domains and the second half antibody binds an epitope within all or a portion of the B7-H4 Ig-V containing domain.

2. The bi-epitopic antibody of claim 1 , wherein the B7-H4 Ig-V containing domain has the sequence of amino acids 29-157 of SEQ ID NO: 73.

3. The bi-epitopic antibody of claim 1 , wherein B7-H4 Ig-C containing domain has the sequence of amino acids 158-250 of SEQ ID NO: 73.

4. The bi-epitopic antibody of claim 1 , wherein the first half antibody comprises:

(a) (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 39, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 40, (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 128, (iv) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 42, (v) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 43, and (vi) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 129;

(b) (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 39, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 40, (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 41, (iv) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 42, (v) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 43, and (vi) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 129;

(d) a VH sequence of SEQ ID NO: 127 and a VL sequence of SEQ ID NO: 126.

5. The bi-epitopic antibody of claim 1 , wherein the second half antibody comprises

(a) (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 58, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 59, (iii) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 60, (iv) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 61, (v) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 62, and (vi) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 63; or

(b) a VH sequence of SEQ ID NO: 56 and a VL sequence of SEQ ID NO: 55.

6. The bi-epitopic antibody of claim 4 , wherein the second half antibody comprises:

(b) a VH sequence of SEQ ID NO: 56 and a VL sequence of SEQ ID NO: 55.

7. The bi-epitopic antibody of claim 1 , wherein the antibody is an IgG1 or IgG4 antibody.

8. The bi-epitopic antibody of claim 1 , wherein the first half antibody comprises a first heavy chain constant region comprising a knob mutation and the second heavy chain comprises a second heavy chain constant region comprising a hole mutation; or wherein the first half antibody comprises a first heavy chain constant region comprising a hole mutation and the second heavy chain comprises a second heavy chain constant region comprising a knob mutation.

9. The bi-epitopic antibody of claim 8 , wherein the antibody is an IgG1 antibody and wherein the knob mutation comprises a T366W mutation.

10. The bi-epitopic antibody of claim 9 , wherein the antibody is an IgG1 antibody and wherein the hole mutation comprises at least one, at least two, or three mutations selected from T366S, L368A, and Y407V.

11. The bi-epitopic antibody of claim 8 , wherein the antibody is an IgG4 antibody and wherein the knob mutation comprises a T366W mutation.

12. The bi-epitopic antibody of claim 11 , wherein the antibody is an IgG4 antibody and wherein the hole mutation comprises at least one, at least two, or three mutations selected from T366S, L368A, and Y407V mutations.

13. The bi-epitopic antibody of claim 1 , wherein:

a) the first half antibody comprises a heavy chain sequence of SEQ ID NO: 159 or 163 and a light chain sequence of SEQ ID NO: 145 or 146;

b) the first half antibody comprises a heavy chain sequence of SEQ ID NO: 160 or 164 and a light chain sequence of SEQ ID NO: 145 or 146;

c) the first half antibody comprises a heavy chain sequence of SEQ ID NO: 161 or 165 and a light chain sequence of SEQ ID NO: 147 or 148; or

d) the first half antibody comprises a heavy chain sequence of SEQ ID NO: 162 or 166 and a light chain sequence of SEQ ID NO: 147 or 148.

14. The bi-epitopic antibody of claim 1 , wherein:

a) the first half antibody comprises a heavy chain sequence of SEQ ID NO: 159 or 163 and a light chain sequence of SEQ ID NO: 145 or 146, and the second half antibody comprises a heavy chain sequence of SEQ ID NO: 162 or 166 and a light chain sequence of SEQ ID NO: 147 or 148; or

b) the first half antibody comprises a heavy chain sequence of SEQ ID NO: 161 or 165 and a light chain sequence of SEQ ID NO: 147 or 148, and the second half antibody comprises a heavy chain sequence of SEQ ID NO: 160 or 164 and a light chain sequence of SEQ ID NO: 145 or 146.

15. A bi-epitopic antibody comprising a first half antibody and a second half antibody, wherein the first half antibody comprises a first VH/VL unit that binds a first epitope of B7-H4, and wherein the second half antibody comprises a second VH/VL unit that binds a second epitope of B7-H4, wherein the first half antibody comprises a heavy chain sequence of SEQ ID NO: 159 or 163 and a light chain sequence of SEQ ID NO: 145, and the second half antibody comprises a heavy chain sequence of SEQ ID NO: 162 or 166 and a light chain sequence of SEQ ID NO: 147.

16. A bi-epitopic antibody comprising a first half antibody and a second half antibody, wherein the first half antibody comprises a first VH/VL unit that binds a first epitope of B7-H4, and wherein the second half antibody comprises a second VH/VL unit that binds a second epitope of B7-H4, wherein the first half antibody comprises a heavy chain sequence of SEQ ID NO: 161 or 165 and a light chain sequence of SEQ ID NO: 147, and the second half antibody comprises a heavy chain sequence of SEQ ID NO: 160 or 164 and a light chain sequence of SEQ ID NO: 145.

17. The bi-epitopic antibody of claim 1 conjugated to a label.

18. The bi-epitopic antibody of claim 17 , wherein the label is a positron emitter.

19. The bi-epitopic antibody of claim 18 , wherein the positron emitter is 89 Zr.

Continuity (2)

Provisional Application 62049701 · Sep 12, 2014

Related Publication 20160159910A1 · Jun 9, 2016

Cited By (5)

US 12,281,165 US 12,435,145 US 12,668,631 US 12,679,892 US 12,697,385